

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**FOSUN PHARMA**

**复星医药**

**上海復星醫藥（集團）股份有限公司**

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 02196)**

**OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the “Announcement in Relation to the Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Chen Yuqing**

*Chairman*

Shanghai, the PRC

13 May 2026

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.*

\* *for identification purposes only*

## **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

### **Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application**

**The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.**

#### **I. Overview**

Recently, the drug registration applications of Tao Hong Si Wu Tang Granules (桃紅四物湯顆粒, the “**Drug**”) submitted by Hebei Wanbang Folon Pharmaceutical Co., Ltd.\* (河北萬邦復臨藥業有限公司), being a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (上海復星醫藥(集團)股份有限公司) (the “**Company**”), was accepted by the National Medical Products Administration recently.

#### **II. General Information and Research Progress of the Drug**

The Drug is a Category 3.1 innovative traditional Chinese medicine. Its main functions are nourishing blood, activating blood circulation and removing blood stasis, and is intended to be used for blood deficiency and blood stasis syndrome, the symptoms of which include irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual blood, abdominal pain and bloating, etc. The prescription of the Drug comes from the formulation named Tao Hong Si Wu Decoction (桃紅四物湯) in the "Fu Ke Bing Jian"(《婦科冰鑒》) written by Chai Dehua (柴得華) from the Qing Dynasty, and has been listed in the "Catalogue of Ancient Classic Famous Recipes (First Batch)" (《古代經典名方目錄(第一批)》) by the National Administration of Traditional Chinese Medicine.

As of April 2026, the Group (i.e., the Company and its subsidiaries/units, the same hereinafter) has invested approximately RMB6.96 million (unaudited) in total in the research and development of the Drug at current stage.

As of the date of this Announcement (i.e. 13 May 2026), only two types of Tao Hong Si Wu Tang Granules have been approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions), in April 2025 and April 2026 respectively. Their sales in China for 2025 cannot yet be retrieved from IQVIA CHPA<sup>1</sup>.

### **III. Impact on the Listed Company and Risk Warning**

The Drug is subject to, among others, the passing of the GMP compliance inspection and the obtaining of drug registration approval before its commercial production. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of the pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

13 May 2026

*\* For identification purposes only*

---

<sup>1</sup> a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.